Literature DB >> 16568812

Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study.

Colleen E Miller1, Mary Ann Jezewski.   

Abstract

This study examined the experiences of a group of patients with relapsing multiple sclerosis who received glatiramer acetate for the treatment of their illness. Heideggerian phenomenologic research methods drove the data analysis process with the Atlas Qualitative Data Analysis software program. The sample was a diverse group of 20 men and women 39-64 years of age who had been diagnosed with MS 1-21 years and taking glatiramer acetate 1-7 years. Several participants had been on other treatments; they related their reasons for choosing this treatment and how they manage to persist with taking the daily injections. The themes included choosing glatiramer acetate, self-managing care, injecting, healthy lifestyle, side effects, support, and participant advice to others. Patients with relapsing MS experience a complex process of adjustment when they are diagnosed with the disease and come to the decision to start aggressively treating the illness. They view glatiramer acetate as an integral part of the formula to maintain control over their bodies and manage the disease. Taking the glatiramer acetate injection every day becomes easier as time goes on. They reported that side effects were minimal and manageable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568812     DOI: 10.1097/01376517-200602000-00008

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  4 in total

1.  Relapsing-remitting multiple sclerosis patients' experience with natalizumab: a phenomenological investigation.

Authors:  Colleen E Miller; Mary Karpinski; Mary Ann Jezewski
Journal:  Int J MS Care       Date:  2012

2.  PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.

Authors:  Abigail M Methley; Stephen Campbell; Carolyn Chew-Graham; Rosalind McNally; Sudeh Cheraghi-Sohi
Journal:  BMC Health Serv Res       Date:  2014-11-21       Impact factor: 2.655

3.  A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).

Authors:  Archibald de Ceuninck van Capelle; Hanneke van der Meide; Frans J H Vosman; Leo H Visser
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

4.  Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication.

Authors:  Eva Van Reenen; Wieke Van Der Borg; Merel Visse; Hanneke Van Der Meide; Leo Visser
Journal:  Int J Qual Stud Health Well-being       Date:  2019-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.